Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis
Tóm tắt
The most common cause of ocular morbidity in developed countries is dry eye, many cases of which are due to lacrimal insufficiency. Dry eye affects approximately 10 million in the United States., most of whom are women. In the U.S. alone, an estimated 2 million Sjögren's syndrome patients have dysfunctional lacrimal glands and severe dry eye, and there is no satisfactory treatment. These patients would benefit if their lacrimal tissue function could be restored. The effect of adenovirus-mediated transfer of tumor necrosis factor (TNF)-α inhibitor gene on induced autoimmune dacryoadenitis was evaluated in a rabbit model. Soluble transgene protein was detected in tears by ELISA for 7 days following transduction. Two weeks after induction of disease with activated lymphocytes, tear production, as determined by Schirmer testing, was reduced by about 40%, while tear film stability, as measured by tear breakup time (BUT), declined by 43%. Adenovirus-mediated gene therapy using AdTNFRp55-Ig given 2 weeks after disease induction, resulted in the return of tear production to normal levels by week 4. In the treated disease group, tear BUT improved significantly by week 4. Rose bengal scores, an indicator of corneal surface defects, increased after disease induction and declined after gene therapy. In the lacrimal gland, the CD4 to CD8 T cell ratio was 4:1 in the disease group compared to 1:2 in the treated group. Infiltration of T cells and CD18+ cells was reduced approximately 50% after gene therapy. We concluded that therapeutic levels of soluble TNF inhibitor were achieved in the lacrimal gland and on the corneal surface. Anti-inflammatory cytokine gene expression might offer a potential therapeutic modality for the treatment of autoimmune dacryoadenitis, once suitable vectors become available.
Tài liệu tham khảo
Lemp MA: Report of the National Eye Institute/industry workshop on clinical trials in dry eyes. CLAO J. 1995, 21: 221-255.
Fox RI: Sjögren's syndrome. Curr Opin Rheum. 1995, 7: 409-416.
Sullivan DA, Wickham DA, Krenzer KL, Rocha EM, Toda I: Aqueous tear deficiency in Sjögren's syndrome: possible causes and potential treatment. Oculodermal Diseases Immunology of Bullous Oculo-muco-cutaneous Disorders. Edited by: Pleyer U, Hartmann C, Sterry W. Buren. 1997, Netherlands: Aeolus Press, 95-152.
Tsubota K, Toda I, Yagi Y, Ogawa Y, Ono M, Yoshino K: Three different types of dry eye syndrome. Cornea. 1994, 13: 202-209.
Fox RI, Kang HI: Pathogenesis of Sjögren's syndrome. Rheum Dis Clin North Am. 1992, 18: 517-538.
Guo Z, Azzarolo AM, Schechter JE, Warren DW, Wood RL, Mircheff AK, Kaslow HR: Lacrimal gland epithelial cells stimulate proliferation in autologous lymphocyte preparations. Exp Eye Res. 2000, 71: 11-22. 10.1006/exer.2000.0856.
Guo Z, Song D, Azzarolo AM, Schechter JE, Warren DW, Wood RL, Mircheff AK, Kaslow HR: Autologous lacrimal-lymphoid mixed-cell reactions induce dacryoadenitis in rabbits. Exp Eye Res. 2000, 71: 23-31. 10.1006/exer.2000.0855.
Zhu Z, Stevenson D, Schechter JE, Mircheff AK, Crow RW, Atkinson R, Ritter T, Bose S, Trousdale MD: Tumor necrosis factor inhibitor gene expression suppresses lacrimal gland immunopathology in a rabbit model of autoimmune dacryoadenitis. Cornea. 2003, 22: 343-351. 10.1097/00003226-200305000-00012.
Kolls J, Peppel K, Silva M, Beutler B: Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci USA. 1994, 91: 215-219.
Ritter T, Schroder G, Risch K, Vergopoulos A, Shean MK, Kolls J, Brock J, Lehmann M, Volk HD: Ischemia/reperfusion injury-mediated down-regulation of adenovirus-mediated gene expression in a rat heart transplantation model is inhibited by co-application of a TNFRp55-Ig chimeric construct. Gene Ther. 2000, 7: 1238-1243. 10.1038/sj.gt.3301222.
Zhu Z, Stevenson D, Ritter T, Schechter JE, Mircheff AK, Kaslow HR, Trousdale MD: Expression of IL-10 and TNF-inhibitor genes in lacrimal gland epithelial cells suppresses their ability to activate lymphocytes. Cornea. 2002, 21: 210-214. 10.1097/00003226-200203000-00018.
Zhu Z, Stevenson D, Schechter JE, Mircheff AK, Atkinson R, Trousdale MD: Lacrimal histopathology and ocular surface disease in a rabbit model of autoimmune dacryoadenitis. Cornea. 2003, 22: 25-32. 10.1097/00003226-200301000-00007.
Van Bijsterveld OP: Diagnostic tests in the Sicca syndrome. Arch Ophthalmol. 1969, 82: 10-14.